142 related articles for article (PubMed ID: 27305046)
21. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial.
Snijders D; Daniels JM; de Graaff CS; van der Werf TS; Boersma WG
Am J Respir Crit Care Med; 2010 May; 181(9):975-82. PubMed ID: 20133929
[TBL] [Abstract][Full Text] [Related]
22. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
[TBL] [Abstract][Full Text] [Related]
23. Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit.
Cavallazzi R; Wiemken T; Arnold FW; Luna CM; Bordon J; Kelley R; Feldman C; Chalmers JD; Torres A; Ramirez J
Respir Med; 2015 Jun; 109(6):743-50. PubMed ID: 25956021
[TBL] [Abstract][Full Text] [Related]
24. The pneumonia severity index predicts time to clinical stability in patients with community-acquired pneumonia.
Arnold F; LaJoie A; Marrie T; Rossi P; Blasi F; Luna C; Fernandez P; Porras J; Weiss K; Feldman C; Rodríguez E; Levy G; Arteta F; Roig J; Rello J; Ramirez J;
Int J Tuberc Lung Dis; 2006 Jul; 10(7):739-43. PubMed ID: 16848334
[TBL] [Abstract][Full Text] [Related]
25. Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH study.
Blasi F; Ostermann H; Racketa J; Medina J; McBride K; Garau J;
Respir Res; 2014 Jan; 15(1):6. PubMed ID: 24450444
[TBL] [Abstract][Full Text] [Related]
26. Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience.
Ioachimescu OC; Ioachimescu AG; Iannini PB
Int J Antimicrob Agents; 2004 Nov; 24(5):485-90. PubMed ID: 15519482
[TBL] [Abstract][Full Text] [Related]
27. Nutritional parameters affecting severity of pneumonia and length of hospital stay in patients with pneumococcal pneumonia: a retrospective cross-sectional study.
Akuzawa N; Naito H
BMC Pulm Med; 2015 Nov; 15():149. PubMed ID: 26608261
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive comparison of clinicoradiological, laboratory, and prognostic factors of community-acquired pneumonia in diabetic and nondiabetic hospitalized patients.
Hashemi SH; Saki F; Borzouei S; Bawand R; Soltanian A
Turk J Med Sci; 2023; 53(6):1776-1785. PubMed ID: 38813518
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis.
Marras TK; Nopmaneejumruslers C; Chan CK
Am J Med; 2004 Mar; 116(6):385-93. PubMed ID: 15006587
[TBL] [Abstract][Full Text] [Related]
30. Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia.
Lui G; Ip M; Lee N; Rainer TH; Man SY; Cockram CS; Antonio GE; Ng MH; Chan MH; Chau SS; Mak P; Chan PK; Ahuja AT; Sung JJ; Hui DS
Respirology; 2009 Nov; 14(8):1098-105. PubMed ID: 19818051
[TBL] [Abstract][Full Text] [Related]
31. Severity and outcomes of community acquired pneumonia in asthmatic patients.
Terraneo S; Polverino E; Cilloniz C; Amaro R; Vennera Mdel C; Gabarrus A; Montull B; Moreno E; Menendez R; Centanni S; Torres A
Respir Med; 2014 Nov; 108(11):1713-22. PubMed ID: 25245791
[TBL] [Abstract][Full Text] [Related]
32. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules.
McCabe C; Kirchner C; Zhang H; Daley J; Fisman DN
Arch Intern Med; 2009 Sep; 169(16):1525-31. PubMed ID: 19752411
[TBL] [Abstract][Full Text] [Related]
33. [Community-acquired pneumonia in hospitalized adult patients. Clinical presentation and prognostic factors].
Saldías F; Mardónez JM; Marchesse M; Viviani P; Farías G; Díaz A
Rev Med Chil; 2002 Dec; 130(12):1373-82. PubMed ID: 12611238
[TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
35. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population.
Murcia JM; González-Comeche J; Marín A; Barberán J; Granizo JJ; Aguilar L; González-Moreno J; González-Pina B; López-Dupla M; Irurzun J;
Clin Microbiol Infect; 2009 Nov; 15(11):1046-50. PubMed ID: 19548926
[TBL] [Abstract][Full Text] [Related]
36. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.
Lindstrom ST; Wong EK
Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892
[TBL] [Abstract][Full Text] [Related]
37. Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia.
Cortoos PJ; Gilissen C; Laekeman G; Peetermans WE; Leenaers H; Vandorpe L; Simoens S
Scand J Infect Dis; 2013 Mar; 45(3):219-26. PubMed ID: 23113827
[TBL] [Abstract][Full Text] [Related]
38. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
Niederman MS; Chang JR; Stewart J; Nusrat R; Nieman RB
Curr Med Res Opin; 2004 May; 20(5):749-56. PubMed ID: 15140342
[TBL] [Abstract][Full Text] [Related]
39. [Factors effecting the duration of hospitalization and mortality in patients with community-acquired pneumonia].
Pişkin N; Aydemir H; Oztoprak N; Akduman D; Celebi G; Seremet Keskin A
Mikrobiyol Bul; 2009 Oct; 43(4):597-606. PubMed ID: 20084912
[TBL] [Abstract][Full Text] [Related]
40. Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial.
Dinh A; Duran C; Ropers J; Bouchand F; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Mellon G; Calin R; Makhloufi S; de Lastours V; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Guillemot D; Renaud B; Claessens YE; Labarère J; Aegerter P; Bedos JP; Crémieux AC;
JAMA Netw Open; 2021 Oct; 4(10):e2129566. PubMed ID: 34652445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
